Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) - Equities researchers at William Blair lowered their FY2027 EPS estimates for Telix Pharmaceuticals Limited American Depositary Shares in a research note issued on Wednesday, March 12th. William Blair analyst A. Hsieh now forecasts that the company will post earnings of $1.44 per share for the year, down from their prior estimate of $1.46. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Telix Pharmaceuticals Limited American Depositary Shares' current full-year earnings is $0.24 per share.
Separately, UBS Group lifted their price target on shares of Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Monday, January 27th.
Get Our Latest Research Report on Telix Pharmaceuticals Limited American Depositary Shares
Telix Pharmaceuticals Limited American Depositary Shares Trading Up 1.7 %
TLX traded up $0.30 during midday trading on Thursday, hitting $17.60. The company had a trading volume of 15,349 shares, compared to its average volume of 27,335. Telix Pharmaceuticals Limited American Depositary Shares has a 52 week low of $14.01 and a 52 week high of $30.36. The stock's 50 day simple moving average is $17.47.
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
Before you consider Telix Pharmaceuticals Limited American Depositary Shares, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals Limited American Depositary Shares wasn't on the list.
While Telix Pharmaceuticals Limited American Depositary Shares currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
